However, clinical evidence of effectiveness of RANKL inhibitors against osteosarcoma or other high-grade malignant bone sarcomas are lacking, even though RANKL expression in bone sarcoma was observed and an antitumor effect in a preclinical model was reported [115,116,117]. This evidence concerns the gene TNFSF11 and bone sarcoma.